PSMA-PET Agents Poised to Advance Imaging in Prostate Cancer

Excerpt:

“Imaging agents for the detection of biochemical recurrent prostate cancer could move beyond computed tomography (CT) and magnetic resonance imaging (MRI) in the near future, with the emergence of prostate-specific membrane antigen (PSMA)-PET, particularly in oligometastatic disease, with a high-detection sensitivity rate, explains Thomas Hope, MD.

“PSMA-PET uses small molecules that bind to PSMA, localizes a prostate cancer tumor, and allows radiologists to image patients after 1 hour to detect small sites of disease. Hope and researchers at the University of California, San Francisco (UCSF) are dedicated to bringing this imaging modality to the FDA for approval with diagnostic data as evidence.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Pivotal Role Remains With Bone-Targeting Agents in mCRPC

Excerpt:

“Prostate cancer researchers are continuing to explore strategies to optimally integrate bone-targeted agents into patient care.

“For example, an ongoing trial is assessing the combination of a radiopharmaceutical, radium-223 dichloride (Xofigo), with an androgen receptor-directed therapy, either abiraterone acetate (Zytiga) or enzalutamide (Xtandi). The open-label, phase IIa study is accruing patients with metastatic castration-resistant prostate cancer (mCRPC). The primary endpoint of the trial, which hopes to enroll 68 patients, is patient bone scan response rate (NCT02034552).”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


ESMO 2017 Press Release: Patients with High Risk Prostate Cancer May Benefit “Equally” From Two New Treatments

Excerpt:

“Patients with high risk prostate cancer starting long-term hormone therapy may benefit from two new treatments, according to late-breaking results from the STAMPEDE trial presented at the ESMO 2017 Congress in Madrid.

“Long-term hormone therapy alone has been the standard of care for patients with high risk locally advanced or metastatic prostate cancer since the 1940s.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


A New Study Claims Prostate Cancer Screenings Significantly Reduce Deaths. Not Everyone Agrees

Excerpt:

“An analysis of two influential studies of prostate cancer screening concludes that the much-debated test “significantly” reduces deaths from the disease, suggesting that current recommendations against routine PSA screening might be steering men away from a lifesaving procedure.

“The analysis, published Monday in Annals of Internal Medicine, drew wildly different reactions, as is often the case with research on PSA screenings. Some experts in cancer screening and statistics said its novel approach was “on shaky ground” and used a “completely unverifiable” methodology that they had “never seen before,” but others praised its “intriguing and innovative approach.” There was one area of agreement, however: “I imagine it’s going to generate some buzz,” said biostatistician Ted Karrison of the University of Chicago.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


A Cancer Doctor Weighs In On CAR-T, Precision Medicine And Pricing Debates

Excerpt:

“Yesterday’s historic FDA approval of the first engineered T-cell treatment for cancer, Novartis’ Kymriah (tisagenlecleucel), was accompanied by inevitable questions about how the product would be priced. In the end, Novartis set the price at $475,000, which was lower than many analysts had predicted, considering the treatment is designed to cure some forms of acute lymphoblastic leukemia (ALL)—and in clinical trials it did just that for most patients.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


A Cancer Conundrum: Too Many Drug Trials, Too Few Patients

Excerpt:

“With the arrival of two revolutionary treatment strategies, immunotherapy and personalized medicine, cancer researchers have found new hope — and a problem that is perhaps unprecedented in medical research.

“There are too many experimental cancer drugs in too many clinical trials, and not enough patients to test them on.

“The logjam is caused partly by companies hoping to rush profitable new cancer drugs to market, and partly by the nature of these therapies, which can be spectacularly effective but only in select patients.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Early Chemo Linked to Improved PFS in High-Volume Metastatic Prostate Cancer

Excerpt:

“Patients with high-volume, castration-naïve metastatic prostate cancer may have superior progression-free survival (PFS) outcomes when treated with early docetaxel, according to findings published online in the European Journal of Cancer.

“Using the Quality-adjusted Time Without Symptoms of disease and Toxicity of treatment (Q-TWiST) method, investigators also determined that the benefits associated with androgen deprivation therapy (ADT) plus docetaxel outweighed the risks associated with the treatment.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Using Alternative Medicine Only for Cancer Linked to Lower Survival Rate

Excerpt:

“Patients who choose to receive alternative therapy as treatment for curable cancers instead of conventional cancer treatment have a higher risk of death, according to researchers from the Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center at Yale School of Medicine and Yale Cancer Center. The findings were reported online by the Journal of the National Cancer Institute.

“There is increasing interest by  and families in pursuing alternative medicine as opposed to conventional  treatment. This trend has created a difficult situation for patients and providers. Although it is widely believed that conventional cancer treatment will provide the greatest chance at cure, there is limited research evaluating the effectiveness of alternative medicine for cancer.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Software Helps Men With Prostate Cancer Choose the Right Treatments

Excerpt:

“Like many men diagnosed with prostate cancer, Bill Pickett faced a tough question when he came to UCLA for treatment: how to fight it?

“Prostate  is one of the more curable cancers—it has a 96 percent survival rate 15 years after diagnosis, according to the American Cancer Society. The options men have after a diagnosis have different side effects and trade-offs. So choosing, for example, between radiation therapy or surgery, can be complicated for a person.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.